Genscript Biotech (HKG:1548) posted an attributable net loss of $129.3 million for the first half, widening from a reported loss of $24.5 million a year earlier.
Loss per share stood at $0.0592, compared with $0.0216 in the year-ago period, according to a Sunday filing with the Hong Kong Exchange.
Revenue increased year over year to $404.2 million for the six months ended June 30 from $518.8 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.